Literature DB >> 21243485

Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.

Erin M Rock1, Jennifer M Goodwin, Cheryl L Limebeer, Aviva Breuer, Roger G Pertwee, Raphael Mechoulam, Linda A Parker.   

Abstract

RATIONALE: The interaction between two non-psychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG), which have been reported to act as a 5-hydroxytryptamine 1A (5-HT(1A)) agonist and antagonist, respectively, was evaluated.
OBJECTIVE: To evaluate the potential of CBG to reverse the anti-nausea, anti-emetic effects of CBD.
MATERIALS AND METHODS: In experiment 1, rats were pre-treated with CBG (0.0, 1, 5, and 10 mg/kg, ip), 15 min prior to being treated with CBD (experiment 1a: VEH or 5 mg/kg, ip) or 8-OH-DPAT (experiment 1b: VEH or 0.01 mg/kg, ip). Thirty minutes later, all rats received a pairing of 0.1% saccharin solution and LiCl (20 ml/kg of 0.15 M, ip). Seventy-two hours later, the rats received a drug-free taste reactivity test with saccharin to evaluate the effects of the treatments on the establishment of conditioned gaping reactions (a model of nausea). As well, conditioned saccharin avoidance was measured. In experiment 2, Suncus murinus were injected with CBG (5 mg/kg, ip) or VEH 15 min prior to CBD (5 mg/kg) or VEH and 30 min later were injected with LiCl (60 ml/kg of 0.15 M, i.p.), and the number of vomiting episodes were measured.
RESULTS: CBD (5 mg/kg) suppressed conditioned gaping in rats and vomiting in shrews, which were reversed by pre-treatment with all doses of CBG. CBG also prevented the anti-nausea effects of 8-OH-DPAT.
CONCLUSIONS: Interactions between moderate doses of CBG and CBD may oppose one another at the 5-HT(1A) receptor in the regulation of nausea and vomiting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21243485     DOI: 10.1007/s00213-010-2157-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.

Authors:  Alessia Ligresti; Aniello Schiano Moriello; Katarzyna Starowicz; Isabel Matias; Simona Pisanti; Luciano De Petrocellis; Chiara Laezza; Giuseppe Portella; Maurizio Bifulco; Vincenzo Di Marzo
Journal:  J Pharmacol Exp Ther       Date:  2006-05-25       Impact factor: 4.030

2.  Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds.

Authors:  H N Eisohly; C E Turner; A M Clark; M A Eisohly
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

3.  Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.

Authors:  Jonathan D Wilkinson; Elizabeth M Williamson
Journal:  J Dermatol Sci       Date:  2006-12-06       Impact factor: 4.563

4.  Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats.

Authors:  Linda A Parker; Raphael Mechoulam; Coralynne Schlievert
Journal:  Neuroreport       Date:  2002-04-16       Impact factor: 1.837

5.  Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism.

Authors:  Kazuhide Hayakawa; Kenichi Mishima; Kohji Abe; Nobuyoshi Hasebe; Fumie Takamatsu; Hiromi Yasuda; Tomoaki Ikeda; Keiichiro Inui; Nobuaki Egashira; Katsunori Iwasaki; Michihiro Fujiwara
Journal:  Neuroreport       Date:  2004-10-25       Impact factor: 1.837

6.  Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.

Authors:  L E Orr; J F McKernan; B Bloome
Journal:  Arch Intern Med       Date:  1980-11

7.  The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats.

Authors:  Cheryl L Limebeer; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2003-01-28       Impact factor: 4.530

8.  Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.

Authors:  Nissar A Darmani; Jano J Janoyan; Jennifer Crim; Juan Ramirez
Journal:  Eur J Pharmacol       Date:  2007-02-16       Impact factor: 4.432

9.  A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew).

Authors:  Magdalena Kwiatkowska; Linda A Parker; Page Burton; Raphael Mechoulam
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

10.  A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol.

Authors:  B K Colasanti
Journal:  J Ocul Pharmacol       Date:  1990
View more
  20 in total

1.  The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.

Authors:  Maria Grazia Cascio; Erica Zamberletti; Pietro Marini; Daniela Parolaro; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-03       Impact factor: 8.739

Review 2.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

3.  Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus).

Authors:  L D O'Brien; C L Limebeer; E M Rock; G Bottegoni; D Piomelli; L A Parker
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

4.  Neuromolecular Mechanisms of Cannabis Action.

Authors:  Yousra Adel; Stephen P H Alexander
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

6.  A hot mess: a case of hyperemesis.

Authors:  Eileen Cheung; Carly Ng; John Foote
Journal:  Can Fam Physician       Date:  2014-07       Impact factor: 3.275

Review 7.  Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

Authors:  Cecilia J Sorensen; Kristen DeSanto; Laura Borgelt; Kristina T Phillips; Andrew A Monte
Journal:  J Med Toxicol       Date:  2016-12-20

Review 8.  Cannabinoid hyperemesis syndrome.

Authors:  Jonathan A Galli; Ronald Andari Sawaya; Frank K Friedenberg
Journal:  Curr Drug Abuse Rev       Date:  2011-12

9.  Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid.

Authors:  John Merrick; Brian Lane; Terri Sebree; Tony Yaksh; Carol O'Neill; Stan L Banks
Journal:  Cannabis Cannabinoid Res       Date:  2016-04-01

10.  Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats.

Authors:  E M Rock; L A Parker
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.